# Combination Drug Therapy for Patients With Hepatitis C

> **NCT00001729** · PHASE3 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 120 (—)

## Conditions studied

- Chronic Hepatitis C
- Fibrosis
- Hemolytic Anemia

## Interventions

- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00001729
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** 120 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001729, "Combination Drug Therapy for Patients With Hepatitis C". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00001729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*